Across TCGA pan-cancer cohorts, LRRC66 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LRRC66 data layer compared with 26 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LRRC66 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated LRRC66 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, THYM, and BLCA are the cancer types where LRRC66 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.